R. Hindes

5.3k total citations · 2 hit papers
31 papers, 2.6k citations indexed

About

R. Hindes is a scholar working on Hepatology, Epidemiology and Infectious Diseases. According to data from OpenAlex, R. Hindes has authored 31 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hepatology, 22 papers in Epidemiology and 9 papers in Infectious Diseases. Recurrent topics in R. Hindes's work include Hepatitis C virus research (23 papers), Hepatitis B Virus Studies (18 papers) and Liver Disease Diagnosis and Treatment (8 papers). R. Hindes is often cited by papers focused on Hepatitis C virus research (23 papers), Hepatitis B Virus Studies (18 papers) and Liver Disease Diagnosis and Treatment (8 papers). R. Hindes collaborates with scholars based in United States, Taiwan and Türkiye. R. Hindes's co-authors include William T. Symonds, Robert H. Hyland, M. Michelle Berrey, Yun‐Fan Liaw, Bruce Kreter, Edward Gane, Evguenia S. Svarovskaia, Xiao Ding, Zachary Goodman and Catherine Stedman and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Gastroenterology.

In The Last Decade

R. Hindes

31 papers receiving 2.6k citations

Hit Papers

Long-Term Entecavir Therapy Results in the Reversal of Fi... 2010 2026 2015 2020 2010 2013 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡
    2010 735 citations Ting‐Tsung Chang, Yun‐Fan Liaw et al. Hepatology profile →
  2. Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C
    2013 542 citations Edward Gane, Catherine Stedman et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
R. Hindes United States 17 2.4k 2.4k 399 97 84 31 2.6k
Brian L. Pearlman United States 18 1.0k 0.4× 919 0.4× 229 0.6× 84 0.9× 81 1.0× 43 1.3k
A Andreana Italy 15 1.0k 0.4× 1.2k 0.5× 161 0.4× 68 0.7× 79 0.9× 28 1.6k
Waldemar Halota Poland 16 1.6k 0.6× 1.6k 0.7× 150 0.4× 69 0.7× 112 1.3× 88 1.9k
Marie‐Françoise Tripodi Italy 13 1.0k 0.4× 1.3k 0.5× 156 0.4× 76 0.8× 97 1.2× 17 1.6k
Peter Ferenci Austria 17 2.4k 1.0× 2.1k 0.9× 477 1.2× 259 2.7× 123 1.5× 41 2.6k
Lisa D. Pedicone United States 20 2.1k 0.9× 3.0k 1.2× 1.5k 3.9× 234 2.4× 120 1.4× 56 3.5k
Giuseppe Cariti Italy 22 869 0.4× 804 0.3× 271 0.7× 60 0.6× 100 1.2× 82 1.1k
David Wyles United States 31 2.0k 0.8× 1.7k 0.7× 865 2.2× 137 1.4× 396 4.7× 110 2.6k
Yılmaz Çakaloğlu Türkiye 26 3.4k 1.4× 3.4k 1.5× 260 0.7× 56 0.6× 89 1.1× 83 3.8k
Marina Núñez Spain 33 2.3k 1.0× 2.3k 1.0× 1.5k 3.7× 65 0.7× 85 1.0× 104 3.4k

Countries citing papers authored by R. Hindes

Since Specialization
Citations

This map shows the geographic impact of R. Hindes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Hindes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Hindes more than expected).

Fields of papers citing papers by R. Hindes

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Hindes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Hindes. The network helps show where R. Hindes may publish in the future.

Co-authorship network of co-authors of R. Hindes

This figure shows the co-authorship network connecting the top 25 collaborators of R. Hindes. A scholar is included among the top collaborators of R. Hindes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Hindes. R. Hindes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gane, Edward, Christian Schwabe, Catherine Stedman, et al.. (2015). LP27 : ACH-3422, A novel nucleotide prodrug inhibitor of HCV NS5B polymerase. Journal of Hepatology. 62. S277–S277. 3 indexed citations
2.
3.
Gane, Edward, Catherine Stedman, Robert H. Hyland, et al.. (2013). Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C. New England Journal of Medicine. 368(1). 34–44. 542 indexed citations breakdown →
4.
Fontana, Robert J., Eric Hughes, Marc Bifano, et al.. (2013). Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C. American Journal of Transplantation. 13(6). 1601–1605. 112 indexed citations
5.
Fontana, Robert J., Eric Hughes, Henry D. Appelman, et al.. (2012). Case report of successful peginterferon, ribavirin, and daclatasvir therapy for recurrent cholestatic hepatitis C after liver retransplantation. Liver Transplantation. 18(9). 1053–1059. 51 indexed citations
6.
7.
Chang, Ting‐Tsung, Yun‐Fan Liaw, Eugene R. Schiff, et al.. (2010). Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡. Hepatology. 52(3). 886–893. 735 indexed citations breakdown →
8.
9.
Sherman, Morris, Cihan Yurdaydın, Halis Şimşek, et al.. (2008). Entecavir therapy for lamivudine‐refractory chronic hepatitis B. Hepatology. 48(1). 99–108. 133 indexed citations
10.
Chang, Ting‐Tsung, You‐Chen Chao, Ching‐Lung Lai, et al.. (2008). Four-Year Treatment with Entecavir Results in High Proportions of Nucleoside-Naïve HBeAg-Positive Patients with Undetectable HBV DNA: Results from Studies ETV-022 and -901. 1 indexed citations
11.
Şentürk, Hakan, Yoav Lurie, Adrián Gadano, et al.. (2007). [517] ETV RE-TREATMENT OF NUCLEOSIDE-NAIVE HBeAg(−) PATIENTS. Journal of Hepatology. 46. S197–S197. 4 indexed citations
12.
Sherman, Morris, Cihan Yurdaydın, Jose D. Sollano, et al.. (2006). Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B. Gastroenterology. 130(7). 2039–2049. 308 indexed citations
13.
Chang, Ting‐Tsung, You‐Chen Chao, Sabahattin Kaymakoğlu, et al.. (2006). ENTECAVIR MAINTAINED VIROLOGIC SUPPRESSION THROUGH 3 YEARS OF TREATMENT IN ANTIVIRALNAı‥VE HBEAG PATIENTS (ETV 022/901). 19 indexed citations
14.
15.
Chang, Ting‐Tsung, Robert G. Gish, Stephanos J. Hadziyannis, et al.. (2005). A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients. Gastroenterology. 129(4). 1198–1209. 199 indexed citations
16.
Gish, Robert G., S. Hadziyannis, J Cianciara, et al.. (2004). 428 Lamivudine-refractory hepatitis B patients can be safely switched directly to entecavir 1 mg daily therapy. Journal of Hepatology. 40. 127–127. 5 indexed citations
17.
Schiff, E., R. Hindes, Anne O’Donnell, Deborah DeHertogh, & Bruce Kreter. (2003). Summary of phase II clinical and laboratory safety experience with Entecavir. Journal of Hepatology. 38. 170–170. 1 indexed citations
18.
Chang, Ting‐Tsung, S. Hadziyannis, J Cianciara, et al.. (2002). Sustained viral load and ALT reduction following 48 weeks of entecavir treatment in subjects with chronic hepatitis B who have failed lamivudine.. Hepatology. 36(4). 21 indexed citations
19.
Hindes, R., et al.. (1993). Nosocomial xanthomonas meningitis/ventriculitis. American Journal of Infection Control. 21(2). 85–85. 1 indexed citations
20.
Hindes, R., Sandra Willey, George M. Eliopoulos, et al.. (1989). Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin. Antimicrobial Agents and Chemotherapy. 33(7). 1019–1022. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Brian L. Pearlman Breakdown of academic impact, for papers by A Andreana Breakdown of academic impact, for papers by Waldemar Halota Breakdown of academic impact, for papers by Marie‐Françoise Tripodi Breakdown of academic impact, for papers by Peter Ferenci Breakdown of academic impact, for papers by Lisa D. Pedicone Breakdown of academic impact, for papers by Giuseppe Cariti Breakdown of academic impact, for papers by David Wyles Breakdown of academic impact, for papers by Yılmaz Çakaloğlu Breakdown of academic impact, for papers by Marina Núñez
Rankless by CCL
2026